“For the first time in many years, a new message is on the lips of the people on the frontlines [of the AIDS response] — together, we will end AIDS,” UNAIDS Executive Director Michel Sidibe writes in the Huffington Post’s “Global Living” blog. He notes, “Just a decade ago, this very thought would have been dismissed,” and asks, “What has changed? Where has this hope come from?” He writes, “It comes from the resilience and steadfastness of the global community, led by people living with HIV, grandmothers, sisters, brothers, mothers, doctors, nurses, scientists, activists to halt the AIDS epidemic from defining our lives.” He provides a recap of the global response, highlighting results, investments, scientific progress, and the protection of human rights, and continues, “Above all, it is people who have changed the face of the AIDS epidemic.” He concludes, “We can end AIDS. We will end AIDS” (7/25).
In this Politico opinion piece, Desmond Tutu, archbishop emeritus of Cape Town, South Africa, and Gerry Elsdon, a South African businesswoman and television host — both tuberculosis (TB) survivors — write that one priority at the XIX International AIDS Conference (AIDS 2012) in Washington, D.C., this week “should be spearheading a joint global effort against HIV and tuberculosis.” They write, “The rationale for a joint effort is clear,” adding, “Where HIV and TB are most common, the epidemics have merged, or are in the process of merging, into a single co-epidemic,” and “[t]hose whose immune systems are weakened by HIV are at extreme risk of dying from TB.” They conclude, “Thanks to a series of recent scientific breakthroughs, this week’s conference is the first in 30 years that has activists seriously contemplating the end of AIDS. Yet to see a real end to AIDS, we must put an end to TB. So let’s combine our efforts to reach these two goals” (7/24).
“At the XIX International AIDS Conference this week in Washington, D.C., Americans should be proud of what we have done to fight HIV/AIDS around the world, and how, together, we are turning the tide against an epidemic once thought to be invincible,” CARE USA President and CEO Helene Gayle writes in this post in Huffington Post’s “Global Motherhood” blog. “At CARE, which fights global poverty by empowering women and girls, we have seen women — particularly young women — remain disproportionately at risk of contracting the disease,” she writes, noting, “The World Health Organization reports that women constitute 60 percent of people living with HIV in sub-Saharan Africa.” She concludes, “Continuing the momentum means staying ahead of the disease and reaching the most vulnerable populations such as the ultra-poor and, in too many places, women and girls” (7/24).
Noting “[a]pproximately 17 million women worldwide are currently living with HIV, with more than a million new infections in women of reproductive age each year,” Suzanne Ehlers, president and CEO of Population Action International (PAI), and Charles Lyons, president and CEO of the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), write in this guest post in the Center for Global Health Policy’s “Science Speaks” blog that “family planning and HIV are inextricably linked, especially for HIV-positive women who are pregnant or may become pregnant.” They continue, “And while addressing unmet family planning needs is essential for all women, family planning services are particularly critical for HIV-positive women who want to postpone pregnancy due to HIV-related illness, or want to access medicines and services that will allow them to give birth to an HIV-negative child” (Barton, 7/24).
OPINION: 'Win-Win Deals' Between Drug Companies, Purchasers Solution To Intellectual Property Debates
In this Foreign Policy opinion piece, Roger Bate, a resident scholar at the American Enterprise Institute specializing in international health policy, discusses in detail the debates over intellectual property protection for drugs in relation to access to these drugs in developing countries and highlights a number of recent cases involving intellectual property legislation in the developing world. “Stricter TRIPS implementation is in the broad public interest because it increases incentives to innovate,” but “TRIPS is really a distraction from the job of increasing medicine access in the developing world,” he writes, concluding, “The solution lies in win-win deals between drug companies and institutional purchasers (domestic health agencies or foreign donors) that segment the market and tier prices sensibly. … [T]he real action is in making hybrid deals that recognize the political realities, and move on” (7/23).
As participants convene this week in Washington, D.C., for the XIX International AIDS Conference (AIDS 2012), “it is impossible to ignore an inconvenient truth: that drug war politics and policies in the United States and many other countries are severely jeopardizing the overall ‘fight against AIDS,'” Mathilde Krim, founding chair of amfAR and a member of the board of the Drug Policy Alliance, and Ethan Nadelmann, founder and executive director of the Drug Policy Alliance, write in the Huffington Post’s “Politics Blog.” They continue, “Too many countries in the world have let their repressive and punitive drug policies get in the way of the public’s health. … The spread of HIV will not be stopped as long as drug use remains criminalized and as long as people who inject drugs are given up for lost” (7/24).
Noting successes with the National HIV/AIDS Strategy and PEPFAR, as well as other domestic and international programs, Rep. Henry Waxman (D-Calif.) writes in a Politico opinion piece, “But this is not enough.” He continues, “The Obama administration has the opportunity to push for policies that can offer developing nations more access to generic ARV therapies,” including supporting intellectual property rules under the Trans-Pacific Partnership “that would help speed up — not impede — generic drug competition in countries like Vietnam.” Waxman adds, “We should also back efforts to give developing countries more flexibility in interpreting the World Trade Organization’s patent rules for medicines,” and the administration “should … promote the Medicines Patent Pool, a bold initiative to bring down prices of HIV medicines by encouraging pharmaceutical companies to voluntarily license their patents and allow generic manufacturers to sell in developing countries.” Waxman concludes that the U.S. should be proud of its leadership on HIV/AIDS, “[b]ut our work is far from done. Supporting reliable access to generic medicines in the developing world is a much-needed step in getting us there” (7/24).
Though “a massive 24-year global effort to eradicate [polio] forever is now within striking distance of its goal, … there is still a very real danger that the entire campaign could come undone,” Jay Winsten, associate dean at the Harvard School of Public Health, and Emily Serazin, a principal in the Washington, D.C. office of the Boston Consulting Group, write in a Wall Street Journal opinion piece. The campaign to eradicate the disease faces geopolitical challenges, “[b]ut the biggest danger faced by the campaign is a dramatic funding shortfall of $945 million — almost half the amount originally budgeted for 2012-13,” they write. “The challenges faced by the polio campaign are emblematic of problems that affect worldwide efforts to conquer vaccine-preventable diseases such as measles and whooping cough,” Winsten and Serazin state and note that a Global Vaccine Action Plan was recently compiled by a huge collaborative effort and endorsed by the World Health Assembly. “With sufficient funding and political will, the massive health and economic benefits of vaccines are indeed attainable,” they conclude (7/24).
In this opinion piece in the Atlantic, Mark Harrington, co-founder and executive director of the Treatment Action Group (TAG), says that stronger leadership from the U.S. is needed in order to end the AIDS epidemic. Harrington notes that “earlier this year, [President Obama] proposed a shocking cut of $550 million to [PEPFAR], the most successful U.S.-funded global health program in history,” and highlights his absence from “the first International AIDS Conference to be held on American soil since … 1990.” He provides “a to do list the president should consider if he wants to walk the walk,” which includes “[f]ully fund[ing] PEPFAR and support[ing] its reauthorization in 2013,” “[f]ully support[ing] the Global Fund to Fight AIDS, Tuberculosis and Malaria,” “[r]eject[ing] the congressional ban on federal funding for needle exchange,” “[r]evis[ing] and revitaliz[ing] the National HIV/AIDS Strategy,” increasing funding for NIH, and “fully funding the research, prevention, care, and treatment” needed to end the epidemic (7/24).
As part of the Guardian’s “Young people’s sexual health matters” series, Doortje Braeken, senior adviser on adolescents and youth at the International Planned Parenthood Federation (IPPF), in an opinion piece reflects upon the recent London Summit on Family Planning, and says “the biggest hurdle is that many societies don’t recognize young people as sexual beings,” and “[o]ther challenges include policy, legal, economic, cultural, educational, service delivery and supply chain management,” as well as data collection. She says the community must “[d]evelop a comprehensive approach to young people’s mental and physical health and empowerment, recognize young people as sexual beings, provide comprehensive sexuality education for all …, train providers properly, and create easily accessible services.” She continues, “Perhaps it’s now time to create a comprehensive, commonly-agreed blueprint of components that are required to achieve the outcomes we all seek with regard to young people’s sexual and reproductive health, and again with components that can be phased in according to each community’s and nation’s need” (7/24).